| Literature DB >> 16257558 |
E Rollman1, A Bråve, A Boberg, L Gudmundsdotter, G Engström, M Isaguliants, K Ljungberg, B Lundgren, P Blomberg, J Hinkula, B Hejdeman, E Sandström, M Liu, B Wahren.
Abstract
The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16257558 DOI： 10.1016/j.micinf.2005.07.017
Source DB: PubMed Journal: Microbes Infect ISSN： 1286-4579 Impact factor: 2.700